Advancements in antibody technology has revolutionized both the diagnostic and therapeutic sciences. As of today, monoclonal antibodies can be produced virtually against any antigen and they have transformed the diagnostic industry in view of their specificity towards specific antigens and almost unlimited production capabilities. In the field of therapeutics, they have changed the treatment possibilities and significantly improved the life expectancies of patients who were earlier having very high unmet needs.

IMARC Group, one of the world’s leading research and advisory firms, in its latest report “Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016” finds that the Indian market for both therapeutic and diagnostic antibodies is expected to grow exponentially in the coming years. Findings from the report suggest that more than 60% of the total antibodies market is currently dominated by diagnostic antibodies. This segment, however, is more mature, has lower entry barriers and is extremely price sensitive. The market for therapeutic antibodies in India, on the other hand, is still in its infancy and more than half of the globally launched therapeutic monoclonal antibodies are currently not even available here. In the coming years, however, we expect this market to explode. Driven by a continuous increase in healthcare expenditures, increasing affordability, and a number of new product launches, we expect the market for therapeutic antibodies to grow at a CAGR of 27% in the next five years.

IMARC’s new report entitled “Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016” provides an analytical and statistical insight into the Indian Antibodies market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of the following aspects of the Indian antibodies market.


Key Aspects Analyzed:

Diagnostic Antibodies

Understanding the strengths, weaknesses, opportunities and challenges in the Indian diagnostic antibodies market

Understanding the technological considerations and regulatory factors in the Indian diagnostic antibodies market

• Evaluating the various types of antibody based diagnostic tests conducted in India and analyzing their strengths and weaknesses
• Understanding the key regulations for registering, manufacturing and importing diagnostics in India

Comprehensive situation analysis of the Indian diagnostic antibodies market
Segments covered: HIV, Hepatitis B, Hepatitis C, Tuberculosis, Dengue, Syphilis and Oncology
Focus of the analysis in each segment:
• Number of tests conducted each year
• Breakup by type of tests conducted
• Current and future market sales
• Average cost of diagnostic tests
• Key players operating in the market

Therapeutic Antibodies

Understanding the strengths, weaknesses, opportunities and challenges in the Indian therapeutic antibodies market

Understanding the technological considerations and regulatory factors in the Indian therapeutic antibodies market
• Evaluation and identification of monoclonal antibodies based on the sources from which they are derived and on the targets against which they act.
• Understanding the key regulations for registering, manufacturing and importing therapeutic antibodies in India.

Evaluating the patent details of all globally marketed monoclonal antibodies in India, US and Europe
• Identifying the patentee name and patent numbers of all in-market monoclonal antibodies in India, US and Europe
• Identifying the monoclonal antibodies that are patent protected in India, US and Europe and those that are not
• Estimating the patent expiries of various monoclonal antibodies in India, US and Europe.

Comprehensive situation analysis of the Indian therapeutic antibodies market
• Analyzing current and future sales of monoclonal antibodies in India
• Identifying all globally launched monoclonal antibodies and understanding their performance and launch status in India
• Analyzing the global and Indian monoclonal antibodies market by Indication
• Evaluation of the top selling monoclonal antibodies
• Key biosimilar antibody development programmes in India and abroad

1 Market Definitions & Methodology
2 Executive Summary
3 Indian Antibodies Market
4 Antibody Based Diagnostics Market in India
4.1 Industry Analysis
4.1.1 Strengths
4.1.2 Weaknesses
4.1.3 Opportunities
4.1.4 Threats
4.2 Technological & Regulatory Assessment
4.2.1 Technological Assessment
4.2.2 Regulatory Assessment
4.3 Market Analysis
4.3.1 Current & Future Sales Trends
4.3.2 Market Segments by Usage
4.3.2.1 HIV Diagnostics: Current Trends & Forecast
4.3.2.2 Hepatitis B Diagnostics: Current Trends & Forecast
4.3.2.3 Hepatitis C Diagnostics: Current Trends & Forecast
4.3.2.4 Tuberculosis Diagnostics: Current Trends & Forecast
4.3.2.5 Dengue Diagnostics: Current Trends & Forecast
4.3.2.6 Pregnancy Diagnostics: Current Trends & Forecast
4.3.2.7 Syphilis Diagnostics: Current Trends & Forecast
4.3.2.8 Oncology Diagnostics: Current Trends & Forecast
5 Therapeutic Antibodies Market in India
5.1 Industry Analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2 Technological & Regulatory Assessment
5.2.1 Technological Assessment
5.2.2 Regulatory Assessment
5.3 Patent Details of Various Monoclonal Antibodies: US, Europe & India
5.4 Market Analysis
5.4.1 Current & Future Sales Trends
5.4.2 Sales Breakup by Molecule
5.4.3 Sales by Indication
5.5 Evaluation of Top Monoclonal Antibodies
5.5.1.1 Avastin
5.5.1.2 Herceptin
5.5.1.3 Rituxan/Mabthera
5.5.1.4 Remicade
5.5.1.5 Humira
5.6 Biosimilar Case Studies
5.6.1 Reditux
5.6.2 Grafeel
5.7 Key Indian & Foreign Biosimilar Antibody Development Programmes

List of Tables

Table 1 1: Monoclonal Antibodies Market: Market Definitions
Table 1 2: India - Immunodiagnostics Market: Market Definitions
Table 2 1: India - Diagnostic Antibodies Market - SWOT Analysis
Table 2 2: India - Executive Summary - Immunodiagnostics Market: Overview of Various Indications, 2010
Table 2 3: India - Therapeutic Antibodies Market - SWOT Analysis
Table 4 1: India - Statistics of Various Indications
Table 4 2: India - Comparison of Rapid & Elisa Tests
Table 4 3: India - Immunodiagnostics Market: Overview of Various Indications, 2010
Table 4 4: India - HIV Diagnostics Market: Key Statistics, 2010
Table 4 5: India - Hepatitis B Diagnostics Market: Key Statistics, 2010
Table 4 6: India - Hepatitis C Diagnostics Market: Key Statistics, 2010
Table 4 7: India - Tuberculosis Diagnostics Market: Key Statistics, 2010
Table 4 8: India - Cancer Diagnostics Market: Overview of Various Cancer Markers
Table 5 1: Globally Launched Monoclonal Antibodies & Their Targets
Table 5 2: US, Europe & India - Patent Details of Various Monoclonal Antibodies
Table 5 3: Global & Indian: Monoclonal Antibodies Market - Statistics of Various Brands
Table 5 4: India - Monoclonal Antibodies Market: Sales of Top Selling Molecules (in INR Million), 2010
Table 5 5: Drug Overview: Avastin
Table 5 6: Drug Overview: Herceptin
Table 5 7: Drug Overview: Rituxan
Table 5 8: Drug Overview: Remicade
Table 5 9: Drug Overview: Humira
Table 5 10: Drug Overview: Reditux
Table 5 11: Companies Developing Herceptin (Trastuzumab) Biosimilars
Table 5 12: Companies Developing Remicade (Infliximab) Biosimilars
Table 5 13: Companies Developing Mabthera (Rituximab) Biosimilars
Table 5 14: Companies Developing Humira (Trastuzumab) Biosimilars
Table 5 15: Companies Developing Other Monoclonal Antibody Biosimilars

List of Figures

Figure 3 1: India - Antibodies Market Forecast, 2010-2016
Figure 3 2: India - Antibodies Market Forecast - Breakup by Segment (in %), 2010-2016
Figure 4 1: India - Overview of Elisa and Rapid Tests
Figure 4 2: India - In-Vitro Diagnostics Market Forecast (in INR Million), 2010-2016
Figure 4 3: India - Immunodiagnostics Market Forecast (in INR Million), 2010-2016
Figure 4 4: India - Immunodiagnostics Market Forecast: Breakup by Indication (in %), 2010 & 2016
Figure 4 5: India - HIV Diagnostics Market Forecast (in INR Million), 2010-2016
Figure 4 6: India - HIV Diagnostics Market: Volume Share by Lab (in %), 2010
Figure 4 7: India - HIV Diagnostics Market: Value & Volume Share of Various Tests (in %), 2010
Figure 4 8: India - Hepatitis B Diagnostics Market Forecast (in INR Million), 2010-2016
Figure 4 9: India - Hepatitis B Diagnostics Market: Share of Various Tests (in %), 2010
Figure 4 10: India - Hepatitis C Diagnostics Market Forecast (in INR Million), 2010-2016
Figure 4 11: India - Hepatitis C Diagnostics Market: Share of Various Tests (in %), 2010
Figure 4 12: India - Tuberculosis Diagnostics Market Forecast (in INR Million), 2010-2016
Figure 4 13: India - Tuberculosis Diagnostics Market: Share of Various Tests (in %), 2010
Figure 4 14: India - Dengue Diagnostics Market Forecast (in INR Million), 2010-2016
Figure 4 15: India - Dengue Diagnostics Market: Volume Share of Various Tests (in %), 2010
Figure 4 16: India - Pregnancy Market Forecast (in INR Million), 2010-2016
Figure 4 17: India - Syphilis Diagnostics Market Forecast (in INR Million), 2010-2016
Figure 4 18: India - Syphilis Diagnostics Market: Volume Share of Various Tests (in %), 2010
Figure 4 19: India - Cancer Diagnostics Market Forecast (in INR Million), 2010-2016
Figure 5 1: Monoclonal Antibodies Based on Their Sources
Figure 5 2: India - Approval Process for a New Drug
Figure 5 3: Global - Monoclonal Antibodies Market Forecast (in INR Million), 2010-2016
Figure 5 4: India - Monoclonal Antibodies Market Forecast (in INR Million), 2010-2016
Figure 5 5: Global - Monoclonal Antibodies Market: Sales Share by Molecule (in %), 2010
Figure 5 6: India - Monoclonal Antibodies Market: Sales Share by Molecule (in %), 2010
Figure 5 7: Global - Monoclonal Antibodies Market by Indication (in %), 2010
Figure 5 8: India - Monoclonal Antibodies Market by Indication (in %), 2010-2016
Figure 5 9: Global - Avastin Sales (in INR Million), 2006- 2010
Figure 5 10: Global - Avastin Sales Forecast (in INR Million), 2010-2016
Figure 5 11: Global - Herceptin Sales (in INR Million), 2006-2010
Figure 5 12: Global - Herceptin Sales Forecast (in INR Million), 2010-2016
Figure 5 13: Global - Rituxan/Mabthera Sales (in INR Million), 2006-2010
Figure 5 14: Global - Rituxan/Mabthera Sales Forecast (in INR Million), 2010-2016
Figure 5 15: Global - Remicade Sales (in INR Million), 2006-2010
Figure 5 16: Global - Remicade Sales Forecast (in INR Million), 2010-2016
Figure 5 17: Global - Humira Sales (in INR Million), 2006-2010
Figure 5 18: Global - Humira Sales Forecast (in INR Million), 2010-2016
Figure 5 19: India - Reditux Sales (in INR Million), 2007-08 - 2010-2011
Figure 5 20: India - Impact of Grafeel on G-CSF Market Size & Prices, 2000-01 - 2009-10